GSK250103P34000
- 0.57
- +0.36+171.43%
GlaxoSmithKline Newsroom
GlaxoSmithKline (GSK.US) has another new indication application for the Class 1 new drug Dermoracimab accepted.
Depemokimab (GSK3511294) is a long-acting IL-5 antagonist that has an extended half-life.
Best Income Ideas for 2025: Stocks, Bonds, and Everything in Between
Express News | GlaxoSmithKline: New Kleran has been approved in China for the treatment of adult chronic sinusitis with nasal polyps.
GSK Wins Chinese Nod for Nucala as Chronic Rhinosinusitis Treatment
GSK (GSK.US) "Mubilizumab" has been approved for a new indication in China.
Chronic sinusitis accompanied by nasal polyps is a chronic inflammatory disease of the nasal cavity or sinuses, which can lead to the growth of soft tissues known as nasal polyps, usually characterized by an increase in eosinophil levels.
GlaxoSmithKline (GSK.US) has submitted for the market approval of its ultra-long-acting IL-5 monoclonal antibody in China.
The CDE website shows that GlaxoSmithKline (GSK.US) has applied for the market launch of depemokimab in the country.
Express News | STIFEL has raised the Target Price for GlaxoSmithKline from $153 to $175.
Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.
On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.
Pfizer's Progress on C. Diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
GSK COVID Antiviral Authorization for Sotrovimab Revoked by FDA
GlaxoSmithKline (GSK) Gets a Hold From Barclays
GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of...
GSK's Combination of Cancer Drugs Shows Positive Results in Late-Stage Trial
GSK's Ovarian Cancer Treatment Meets Primary Endpoint in Late-stage Study
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
GSK (GSK.US) monoclonal antibody first-line therapy has received FDA breakthrough therapy designation for the treatment of rectal cancer.
The USA FDA has granted Breakthrough Therapy Designation (BTD) to its PD-1 inhibitor Jemperli (dostarlimab) for the treatment of locally advanced mismatch repair-deficient (dMMR)/high microsatellite instability (MSI-H) colorectal cancer.
CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana